Zhi-Yong Peng1, Lester A H Critchley, Benny S P Fok. 1. Department of Anaesthesia and Intensive Care, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong, China.
Abstract
OBJECTIVE: To determine the dose-response effects of noradrenaline on the systemic and renal circulations during septic shock. DESIGN AND SETTING: Prospective controlled experiment in a university animal laboratory. SUBJECTS: Eight anaesthetized dogs. INTERVENTIONS: Transonic flow probes were surgically placed on the aorta via a left lateral thoracotomy and on the left renal artery. Blood pressure was measured from the femoral artery. Acute bacteraemia shock was induced by injecting Escherichia coli bacteria intravenously. Increasing doses of noradrenaline (0.1, 0.2, 0.3, 0.4, 0.5 microg kg(-1) min(-1)) were infused intravenously for 30 min at 30-min intervals. The model was first validated in four dogs. MEASUREMENTS AND RESULTS: Mean arterial pressure, central venous pressure, cardiac output, and renal blood flow were measured. Systemic vascular resistance was derived. Induction of bacteraemia decreased mean arterial pressure, central venous pressure and systemic vascular resistance. Cardiac output slightly increased. Noradrenaline produced linear dose-dependent increases in both mean arterial pressure and systemic vascular resistance. The response was attenuated during bacteraemia. Under non-bacteraemic conditions the maximum dose of noradrenaline reduced the renal blood flow from 12+/-1 to 10+/-1 ml kg(-1) min(-1). Bacteraemia further reduced renal blood flow to 7+/-1 ml kg(-1) min(-1), which was partly restored by the maximum dose of noradrenaline to 11+/-3 ml kg(-1) min(-1). CONCLUSIONS: Noradrenaline can restore mean arterial pressure in bacteraemic shock and increases in mean arterial pressure are dose-dependent. The noradrenaline response is attenuated by bacteraemic shock. In bacteraemic shock noradrenaline also improves renal perfusion, as perfusion pressure increases. However, renal blood flow is not fully restored, suggesting that an element of impairment of renal blood flow exists due to the bacteraemia or noradrenaline.
OBJECTIVE: To determine the dose-response effects of noradrenaline on the systemic and renal circulations during septic shock. DESIGN AND SETTING: Prospective controlled experiment in a university animal laboratory. SUBJECTS: Eight anaesthetized dogs. INTERVENTIONS: Transonic flow probes were surgically placed on the aorta via a left lateral thoracotomy and on the left renal artery. Blood pressure was measured from the femoral artery. Acute bacteraemia shock was induced by injecting Escherichia coli bacteria intravenously. Increasing doses of noradrenaline (0.1, 0.2, 0.3, 0.4, 0.5 microg kg(-1) min(-1)) were infused intravenously for 30 min at 30-min intervals. The model was first validated in four dogs. MEASUREMENTS AND RESULTS: Mean arterial pressure, central venous pressure, cardiac output, and renal blood flow were measured. Systemic vascular resistance was derived. Induction of bacteraemia decreased mean arterial pressure, central venous pressure and systemic vascular resistance. Cardiac output slightly increased. Noradrenaline produced linear dose-dependent increases in both mean arterial pressure and systemic vascular resistance. The response was attenuated during bacteraemia. Under non-bacteraemic conditions the maximum dose of noradrenaline reduced the renal blood flow from 12+/-1 to 10+/-1 ml kg(-1) min(-1). Bacteraemia further reduced renal blood flow to 7+/-1 ml kg(-1) min(-1), which was partly restored by the maximum dose of noradrenaline to 11+/-3 ml kg(-1) min(-1). CONCLUSIONS:Noradrenaline can restore mean arterial pressure in bacteraemic shock and increases in mean arterial pressure are dose-dependent. The noradrenaline response is attenuated by bacteraemic shock. In bacteraemic shock noradrenaline also improves renal perfusion, as perfusion pressure increases. However, renal blood flow is not fully restored, suggesting that an element of impairment of renal blood flow exists due to the bacteraemia or noradrenaline.
Authors: Miriam M Treggiari; Jacques-André Romand; Dominique Burgener; Peter M Suter; Anders Aneman Journal: Crit Care Med Date: 2002-06 Impact factor: 7.598
Authors: Steven M Hollenberg; Tom S Ahrens; Djillali Annane; Mark E Astiz; Donald B Chalfin; Joseph F Dasta; Stephen O Heard; Claude Martin; Lena M Napolitano; Gregory M Susla; Richard Totaro; Jean-Louis Vincent; Sergio Zanotti-Cavazzoni Journal: Crit Care Med Date: 2004-09 Impact factor: 7.598
Authors: Peter Andrews; Elie Azoulay; Massimo Antonelli; Laurent Brochard; Christian Brun-Buisson; Geoffrey Dobb; Jean-Yves Fagon; Herwig Gerlach; Johan Groeneveld; Jordi Mancebo; Philipp Metnitz; Stefano Nava; Jerome Pugin; Michael Pinsky; Peter Radermacher; Christian Richard; Robert Tasker Journal: Intensive Care Med Date: 2006-02-18 Impact factor: 17.440
Authors: Manuel Pequito; Hélène Amory; Brieuc de Moffarts; Valeria Busoni; Didier Serteyn; Charlotte Sandersen Journal: Can Vet J Date: 2013-02 Impact factor: 1.008
Authors: Stéphane Deruddre; Gaëlle Cheisson; Jean-Xavier Mazoit; Eric Vicaut; Dan Benhamou; Jacques Duranteau Journal: Intensive Care Med Date: 2007-05-08 Impact factor: 17.440